OXiGENE, INC. COMMON STOCKUnderwriting Agreement • December 15th, 2005 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
Exhibit 4.2 OXiGENE, INC. One Copley Place, Suite 602, Boston, MA 02116 July 8, 1998 American Stock Transfer & Trust Company 6201 15th Avenue 3rd Fl. Brooklyn, New York 11219 Attn: Herb Lemmer Re: Amendment to Warrant Agreement...Warrant Agreement • July 9th, 1998 • Oxigene Inc • Biological products, (no disgnostic substances)
Reference is made to the Warrant Agreement, dated August 26, 1994 (the "Agreement"), by and between OXiGENE, Inc., a Delaware corporation (the "Company") and American Stock Transfer & Trust Company (the "Warrant Agent") in its capacity as the Company's transfer agent and warrant registrar, as amended by letter agreement dated September 19, 1994.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 23rd, 2014 • Oxigene Inc • Biological products, (no disgnostic substances)
This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the “Purchase Agreement”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 1st, 2021 • Oncotelic Therapeutics, Inc. • Pharmaceutical preparations
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of November 24, 2021, by and between ONCOTELIC THERAPEUTICS, INC., a Delaware corporation, with headquarters located at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 (the “Company”), and _______________________, a ___________________________________________, with its address at _____________________________ (the “Buyer”).
Exhibit 10.14 TERMINATION AGREEMENT THIS TERMINATION AGREEMENT (this "Agreement") is entered into as of February 15, 2002 (the "Effective Date"), by and between OXiGENE Europe AB, a company duly organized and existing under the laws of Sweden and...Termination Agreement • August 14th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances) • New Jersey
UNDERWRITING AGREEMENTOxigene Inc • October 30th, 1996 • Biological products, (no disgnostic substances) • New York
Exhibit 10.22 OXiGENE Inc. Restricted Stock Agreement for Employees This Restricted Stock Agreement (this "Agreement") is made as of the 2nd day of January 2002, between OXiGENE Inc., a Delaware corporation (the "Company"), David Chaplin ("Grantee")....Restricted Stock Agreement • August 14th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
COMMON STOCK PURCHASE WARRANT OXIGENE, INC.Oxigene Inc • August 29th, 2013 • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, H.C. Wainwright & Co., LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the 1 year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from OXiGENE, Inc., a Delaware corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued by the Company as of the date hereof pursuant to Section A(2) of the letter agreement, dated as of May 16, 2013, as amended and restated, between the Company and H.C. Wainwright & Co., LLC.
RECITALSLease • May 3rd, 2006 • Oxigene Inc • Biological products, (no disgnostic substances)
Exhibit 10.13 EMPLOYMENT AGREEMENT This Employment Agreement (this "Agreement") is entered into as of January 2, 2002, by and between OXiGENE INC., a Delaware corporation with its principal offices at 321 Arsenal Street, Watertown, Massachusetts 02472...Employment Agreement • August 14th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
COPLEY PLACE BOSTON, MASSACHUSETTS OFFICE LEASEOffice Lease • April 15th, 1998 • Oxigene Inc • Biological products, (no disgnostic substances) • Massachusetts
COMMON STOCK PURCHASE WARRANT MATEON THERAPEUTICS, INC.Common Stock Purchase Warrant • June 13th, 2017 • Mateon Therapeutics Inc • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK PURCHASE WARRANT` (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 PM New York City time on , 202 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Mateon Therapeutics, Inc., a Delaware corporation (the “Company”), up to shares of common stock, par value $0.01 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 16th, 2017 • Mateon Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of , 2017, between Mateon Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 1st, 2021 • Oncotelic Therapeutics, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 25, 2021, by and between ONCOTELIC THERAPEUTICS, INC., a Delaware corporation, with its address at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 (the “Company”), and GENEVA ROTH REMARK HOLDINGS, INC., a New York corporation, with its address at 111 Great Neck Road, Suite 216, Great Neck, NY 11021 (the “Buyer”).
Exhibit 10.15 EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement") is entered into as of October 23, 2000, between OXiGENE Inc., a Delaware corporation ("OXiGENE" or the "Company"), and Mr. Frederick W. Driscoll (the "Executive"). W I T N...Employment Agreement • August 14th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances) • Massachusetts
December 4,2006Oxigene Inc • May 7th, 2007 • Biological products, (no disgnostic substances) • Massachusetts
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 7th, 2021 • Oncotelic Therapeutics, Inc. • Pharmaceutical preparations • Nevada
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 3, 2021, by and between Oncotelic Therapeutics, Inc., a Delaware corporation (the “Company”), and PEAK ONE OPPORTUNITY FUND, L.P., a Delaware limited partnership (together with it permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the equity purchase agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
Exhibit 10.14 CONFIDENTIAL TREATMENT REQUESTED AS TO PORTIONS OF THIS DOCUMENT, WHICH PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURTIES AND EXCHANGE COMMISSION. TERMINATION AGREEMENT THIS TERMINATION AGREEMENT (this "Agreement") is...Confidential Treatment • May 15th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances) • New Jersey
COMMON STOCK PURCHASE WARRANT OXIGENE, INC.Oxigene Inc • May 23rd, 2014 • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year and three month anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from OXiGENE, Inc., a Delaware corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 11th, 2010 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 10, 2010, is by and among OXiGENE, Inc., a Delaware corporation with offices located at 701 Gateway Blvd, Suite 210, South San Francisco, CA 94080 (the “Company”), and each of the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”).
EXHIBIT 10.1Employment Agreement • May 7th, 2007 • Oxigene Inc • Biological products, (no disgnostic substances) • Massachusetts
AGREEMENTAgreement • March 30th, 2000 • Oxigene Inc • Biological products, (no disgnostic substances) • Massachusetts
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • May 7th, 2007 • Oxigene Inc • Biological products, (no disgnostic substances)
Exhibit 10.17 EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement') is entered into as of April 1st, 2001, between OXiGENE Inc., a Delaware corporation ("OXiGENE," or the "Company"), and Dr. David Chaplin (the "Executive"). W I T N E S S E...Employment Agreement • August 14th, 2002 • Oxigene Inc • Biological products, (no disgnostic substances) • Massachusetts
FORM OF SECURITIES PURCHASE AGREEMENTForm of Securities Purchase Agreement • February 14th, 2014 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 12, 2014, between OXiGENE, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
EQUITY PURCHASE AGREEMENTEquity Purchase Agreement • May 7th, 2021 • Oncotelic Therapeutics, Inc. • Pharmaceutical preparations • Nevada
This equity purchase agreement is entered into as of May 3, 2021 (this “Agreement”), by and between Oncotelic Therapeutics, Inc., a Delaware corporation (the “Company”), and Peak One Opportunity Fund, L.P., a Delaware limited partnership (the “Investor”).
AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENTEmployment Agreement • July 11th, 2007 • Oxigene Inc • Biological products, (no disgnostic substances)
STOCK PURCHASE WARRANT To Purchase 150,000 Shares of Common Stock of OXiGENE, Inc.Oxigene Inc • June 20th, 2003 • Biological products, (no disgnostic substances)
THIS STOCK PURCHASE WARRANT CERTIFIES that, for value received, Roth Capital Partners, LLC (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after June 10, 2003 (the “Initial Exercise Date”) and on or prior to the close of business on June 9, 2008 (the “Termination Date”) but not thereafter, to subscribe for and purchase from OXiGENE, Inc., a corporation incorporated in the State of Delaware (the “Company”), up to 150,000 shares (the “Warrant Shares”) of Common Stock, par value $0.01 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock (the “Exercise Price”) under this Warrant shall be $12.00, subject to adjustment hereunder. The Exercise Price and the number of Warrant Shares for which the Warrant is exercisable shall be subject to adjustment as provided herein. Capitalized terms used and not otherwise defined herein shall have the meanings set fo
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 20th, 2003 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 10, 2003, among OXiGENE, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (each a “Purchaser” and collectively the “Purchasers”); and
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 21st, 2008 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 19, 2008, is by and between OXiGENE, INC. (the “Company”) and KINGSBRIDGE CAPITAL LIMITED (the “Investor”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 18th, 2019 • Mateon Therapeutics Inc • Pharmaceutical preparations • Nevada
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April , 2019, is entered into by and between MATEON THERAPEUTICS, INC., a Delaware corporation (the “Company”) and PEAK ONE OPPORTUNITY FUND, L.P., a Delaware limited partnership (the “Buyer”).
FORM OF REGISTRATION RIGHTS AGREEMENTForm of Registration Rights Agreement • September 20th, 2013 • Oxigene Inc • Biological products, (no disgnostic substances)
This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the “Purchase Agreement”).
COLLABORATIVE RESEARCH AGREEMENT -------------------------------- This agreement ("AGREEMENT") is made as of August 1, 1997 ("EFFECTIVE DATE") by and between BOSTON MEDICAL CENTER CORPORATION (hereinafter referred to as "BMCC"), a Massachusetts...Collaborative Research Agreement • April 15th, 1998 • Oxigene Inc • Biological products, (no disgnostic substances) • Massachusetts
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 20th, 2003 • Oxigene Inc • Biological products, (no disgnostic substances) • New York
This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 10, 2003, by and among OXiGENE, Inc., a Delaware corporation (the “Company”), and the investors signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).
ONCOTELIC THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANTCommon Stock Purchase Warrant • July 13th, 2023 • Oncotelic Therapeutics, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) of Oncotelic Therapeutics, Inc., a corporation duly organized and validly existing under the laws of Delaware (the “Company”), is issued to the Holder (as defined below) as part of a unit purchased by the Holder from the Company pursuant to which the Holder is also purchasing from the Company notes convertible into shares of its Common Stock, $0.01 par value per share (the “Common Stock”) warrants to purchase 250,000 Common Stock (the “Offering”).
